• 1
    Zitvogel, L., Tesniere, A. and Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006. 6: 715727.
  • 2
    Chen, L., Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004. 4: 336347.
  • 3
    Linsley, P. S., Clark, E. A. and Ledbetter, J. A., T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A 1990. 87: 50315035.
  • 4
    Krummel, M. F. and Allison, J. P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995. 182: 459465.
  • 5
    Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B. et al., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994. 1: 405413.
  • 6
    Khayyamian, S., Hutloff, A., Buchner, K., Grafe, M., Henn, V., Kroczek, R. A. and Mages, H. W., ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci USA 2002. 99: 61986203.
  • 7
    Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I. and Kroczek, R. A., ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999. 397: 263266.
  • 8
    Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G. et al., T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999. 402: 827832.
  • 9
    Dong, C., Juedes, A. E., Temann, U. A., Shresta, S., Allison, J. P., Ruddle, N. H. and Flavell, R. A., ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001. 409: 97101.
  • 10
    McAdam, A. J., Greenwald, R. J., Levin, M. A., Chernova, T., Malenkovich, N., Ling, V., Freeman, G. J. et al., ICOS is critical for CD40-mediated antibody class switching. Nature 2001. 409: 102105.
  • 11
    Yao, S., Zhu, Y., Zhu, G., Augustine, M., Zheng, L., Goode, D. J., Broadwater, M. et al., B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011. 34: 729740.
  • 12
    Tamura, H., Dan, K., Tamada, K., Nakamura, K., Shioi, Y., Hyodo, H., Wang, S. D. et al., Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 2005. 11: 57085717.
  • 13
    Maeda, A., Yamamoto, K., Yamashita, K., Asagoe, K., Nohgawa, M., Kita, K., Iwasaki, H. et al., The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Br J Haematol 1998. 102: 12571262.
  • 14
    Whiteway, A., Corbett, T., Anderson, R., Macdonald, I. and Prentice, H. G., Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 2003. 120: 442451.
  • 15
    Graf, M., Reif, S., Hecht, K., Pelka-Fleischer, R., Kroell, T., Pfister, K. and Schmetzer, H., High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005. 84: 287297.
  • 16
    Dolen, Y. and Esendagli, G., Myeloid leukemia cells with a B7–2+ subpopulation provoke Th-cell responses and become immunosuppressive through the modulation of B7 ligands. Eur J Immunol 2013. 43: 747757.
  • 17
    Dong, H., Zhu, G., Tamada, K. and Chen, L., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999. 5: 13651369.
  • 18
    Tseng, S. Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I. and Shalabi, A. et al., B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001. 193: 839846.
  • 19
    Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J. et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000. 192: 10271034.
  • 20
    Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H. and Honjo, T., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996. 8: 765772.
  • 21
    Yao, S., Wang, S., Zhu, Y., Luo, L., Zhu, G., Flies, S., Xu, H. et al., PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009. 113: 58115818.
  • 22
    Said, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J. et al., Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010. 16: 452459.
  • 23
    Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C. et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002. 8: 793800.
  • 24
    Zou, W. and Chen, L., Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008. 8: 467477.
  • 25
    Chen, X., Liu, S., Wang, L., Zhang, W., Ji, Y. and Ma, X., Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 2008. 7: 622627.
  • 26
    Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S. et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006. 66: 33813385.
  • 27
    Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M., Altman, J. D. and Ahmed, R., Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998. 188: 22052213.
  • 28
    Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S. et al., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012. 4: 127137.
  • 29
    Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D. et al., Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012. 366: 24432454
  • 30
    Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E. et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010. 28: 31673175.